Pure Global

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients - Trial NCT06008093

Access comprehensive clinical trial information for NCT06008093 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 280 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06008093
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06008093
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).

Study Focus

Durvalumab

Interventional

drug

Sponsor & Location

AstraZeneca

Timeline & Enrollment

Phase 3

Oct 16, 2023

Oct 22, 2031

280 participants

Primary Outcome

Overall survival (OS),OS in subset of randomized participants with STK11 or KEAP1 mutations and/or co-mutations

Summary

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in
 combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in
 metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations
 in STK11, KEAP1, or KRAS.

ICD-10 Classifications

Carcinoma in situ: Bronchus and lung
Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06008093

Non-Device Trial